Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
Clinical endpoint
Progression-free survival
Refractory (planetary science)
DOI:
10.1200/jco.20.02712
Publication Date:
2021-01-25T21:00:56Z
AUTHORS (24)
ABSTRACT
As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) for recurrent or metastatic NPC (RM-NPC) refractory standard chemotherapy.In this single-arm, multicenter phase II study, patients with RM-NPC received 3 mg/kg toripalimab once every 2 weeks via intravenous infusion until confirmed disease progression unacceptable toxicity. The primary end point objective response rate (ORR). secondary points included duration (DOR), progression-free survival (PFS), overall (OS).Among all 190 patients, ORR 20.5% median DOR 12.8 months, PFS 1.9 OS 17.4 months. Among 92 who failed at least two lines systemic chemotherapy, 23.9%. ORRs were 27.1% 19.4% in PD-L1+ PD-L1- respectively (P = .31). Patients ≥ 50% decrease plasma Epstein-Barr virus (EBV) DNA copy number on day 28 had significantly better than those < decrease, 48.3% versus 5.7% .0001). Tumor mutational burden value 0.95 muts/mega-base cohort predictive response. Whole-exome sequencing results from 174 revealed that genomic amplification 11q13 region ETV6 alterations poor responses toripalimab.The POLARIS-02 demonstrated manageable safety profile durable clinical chemorefractory NPC. An early EBV correlated favorable
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (39)
CITATIONS (233)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....